Market closed
Fate Therapeutics/$FATE
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Fate Therapeutics
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
Ticker
$FATE
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
181
Website
FATE Metrics
BasicAdvanced
$191M
Market cap
-
P/E ratio
-$1.64
EPS
1.88
Beta
-
Dividend rate
Price and volume
Market cap
$191M
Beta
1.88
52-week high
$8.83
52-week low
$1.59
Average daily volume
4.4M
Financial strength
Current ratio
8.292
Quick ratio
8.096
Long term debt to equity
25.415
Total debt to equity
27.317
Management effectiveness
Return on assets (TTM)
-22.11%
Return on equity (TTM)
-46.59%
Valuation
Price to revenue (TTM)
13.603
Price to book
0.53
Price to tangible book (TTM)
0.53
Price to free cash flow (TTM)
-1.38
Growth
Revenue change (TTM)
-87.34%
Earnings per share change (TTM)
-7.08%
3-year revenue growth (CAGR)
-37.35%
3-year earnings per share growth (CAGR)
-8.22%
What the Analysts think about FATE
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Fate Therapeutics stock.
FATE Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
FATE Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
FATE News
AllArticlesVideos
Fate Therapeutics Presents New Phase 1 Clinical Data of FT819 Off-the-shelf, CAR T-cell Product Candidate for Systemic Lupus Erythematosus
GlobeNewsWire·2 weeks ago
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewsWire·3 weeks ago
Fate Therapeutics Announces Leadership Transition
GlobeNewsWire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Fate Therapeutics stock?
Fate Therapeutics (FATE) has a market cap of $191M as of December 24, 2024.
What is the P/E ratio for Fate Therapeutics stock?
The price to earnings (P/E) ratio for Fate Therapeutics (FATE) stock is 0 as of December 24, 2024.
Does Fate Therapeutics stock pay dividends?
No, Fate Therapeutics (FATE) stock does not pay dividends to its shareholders as of December 24, 2024.
When is the next Fate Therapeutics dividend payment date?
Fate Therapeutics (FATE) stock does not pay dividends to its shareholders.
What is the beta indicator for Fate Therapeutics?
Fate Therapeutics (FATE) has a beta rating of 1.88. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.